Penn Medicine 2020 Updates in Oncology

 

Penn Medicine 2020 Updates in Oncology
Avatar

2020 Adjuvant Escalation and De-escalation in Early Stage BC: Is T-DM1/Pt Superior to THP for High-risk HER2+ Disease? 1 Year of Capecitabine vs. Observation in High-risk TNBC - Which Option Is Superior? Is There a Benefit to Anthracycline in HER2+ Disease?

By Penn Medicine 2020 Updates in Oncology FEATURING Angela DeMichele
By Penn Medicine 2020 Updates in Oncology FEATURING Angela DeMichele
0 views
July 13, 2020
Comments 1
Login to view comments. Click here to Login

Featured Video

06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
Videos
11:54
Penn Medicine 2020 Updates in Oncology

Managing mNSCLC Patients: DFS Data on Adjuvant Osimertinib After Res…

Feat. J. Bauml
05:47
Penn Medicine 2020 Updates in Oncology

Managing mNSCLC Patients With a Molecular Target: How Promising Are …

Feat. J. Bauml
07:29
Penn Medicine 2020 Updates in Oncology

Myeloma Management Strategies: Efficacy Analysis of 1L Options &…

Feat. D. Vogl
12:25
Penn Medicine 2020 Updates in Oncology

Emerging Data from 2020 ASCO Update: How Has SARS-CoV-2 Cancer Patie…

Feat. C. Aggarwal
11:23
Penn Medicine 2020 Updates in Oncology

COVID-19 Database Learnings and National Organization Responses: Wha…

Feat. L. Shulman
08:50
Penn Medicine 2020 Updates in Oncology

COVID-19 Thrombotic Manifestation Review: How Common Is VTE in ICU P…

Feat. A. Pishko
13:44
Penn Medicine 2020 Updates in Oncology

2020 ASCO Penn Medicine Update on Cancer Care During COVID-19: Which…

Feat. L. Schuchter
09:17
Penn Medicine 2020 Updates in Oncology

2020 ASCO Update on CLL: Does Time-limited Triplet Therapy Induce Ra…

Feat. J. Gerson
12:24
Penn Medicine 2020 Updates in Oncology

2020 ASCO Update on Lymphomas: Should Pembro Be New SoC in R/R cHL? …

Feat. J. Gerson
09:38
Penn Medicine 2020 Updates in Oncology

ASCO Update on MM: Does Selinexor Triplet vs. SoC Improve PFS? How t…

Feat. D. Vogl
07:57
Penn Medicine 2020 Updates in Oncology

ASCO Update on Myeloma: How Promising Are BCMA CAR-T & BCMA x CD…

Feat. D. Vogl
06:49
Penn Medicine 2020 Updates in Oncology

2020 ASCO Update on mUC: Does the Earlier Use of a Switch Maintenanc…

Feat. V. Narayan
05:45
Penn Medicine 2020 Updates in Oncology

2020 ASCO Update on Prostate Cancer: How Effective Are Recently FDA …

Feat. V. Narayan
06:07
Penn Medicine 2020 Updates in Oncology

2020 ASCO Update on RCC: IO + TKIs - Is There Long-term Efficacy?

Feat. V. Narayan
14:07
Penn Medicine 2020 Updates in Oncology

2020 Update on MBC: Should Treatment of De Novo Disease Include Loco…

Feat. A. DeMichele
13:03
Penn Medicine 2020 Updates in Oncology

2020 Adjuvant Escalation and De-escalation in Early Stage BC: Is T-D…

Feat. A. DeMichele
06:51
Penn Medicine 2020 Updates in Oncology

2020 ASCO GI Cancer Update: Are CPIs Superior to 2nd Line Chemo in S…

Feat. J. Eads
08:54
Penn Medicine 2020 Updates in Oncology

2020 ASCO GI Cancer Update: Is There a Difference in Survival With F…

Feat. J. Eads
11:32
Penn Medicine 2020 Updates in Oncology

2020 ASCO CRC Update: Encorafenib and Cetuximab in BRAF V600 mCRC, I…

Feat. J. Eads
21:08
Penn Medicine 2020 Updates in Oncology

2020 ASCO Penn Medicine Breaking News: Anticoagulation Regimens Duri…

Feat. J. Bauml, P. Kumar, L. Schuchter, J. Eads, D. Mintzer, J. Gerson, A. Pishko